Literature DB >> 26998033

Clinico-microbiological study and antibiotic resistance profile of mecA and ESBL gene prevalence in patients with diabetic foot infections.

Waqas Nasir Chaudhry1, Rabia Badar1, Muhsin Jamal1, Jason Jeong1, Jamal Zafar1, Saadia Andleeb1.   

Abstract

Diabetic foot infections (DFIs) constitute a major complication of diabetes mellitus. DFIs contribute to the development of gangrene and non-traumatic lower extremity amputations with a lifetime risk of up to 25%. The aim of the present study was to identify the presence of neuropathy and determine the ulcer grade, microbial profile and phenotypic and genotypic prevalence of the methicillin-resistance gene mecA and extended spectrum β-lactamase (ESBL)-encoding genes in bacterial isolates of DFI in patients registered at the Pakistan Institute of Medical Sciences (Islamabad, Pakistan). The results indicated that 46/50 patients (92%), exhibited sensory neuropathy. The most common isolate was Staphylococcus aureus (25%), followed by Pseudomonas aeruginosa (P. aeruginosa; 18.18%), Escherichia coli (16.16%), Streptococcus species (spp.) (15.15%), Proteus spp. (15.15%), Enterococcus spp. (9%) and Klebsiella pneumoniae (K. pneumoniae; 3%). The prevalence of the mecA gene was found to be 88% phenotypically and 84% genotypically. K. pneumoniae was shown to have the highest percentage of ESBL producers with a prevalence of 66.7% by double disk synergy test, and 100% by the cefotaxime + clavulanic acid/ceftazidime + clavulanic acid combination disk test. P. aeruginosa and K. pneumoniae had the highest (100%) proportion of metallo β-lactamase producers as identified by the EDTA combination disk test. The overall prevalence of β-lactamase (bla)-CTX-M, bla-CTX-M-15, bla-TEM, bla-OXA and bla-SHV genes was found to be 76.9, 76.9, 75.0, 57.7 and 84.6%, respectively, in gram-negative DFI isolates. The prevalence of mecA and ESBL-related genes was found to be alarmingly high in DFIs, since these genes are a major cause of antibiotic treatment failure.

Entities:  

Keywords:  antibiotic resistance; diabetic foot ulcer; extended spectrum β-lactamase; prevalence

Year:  2016        PMID: 26998033      PMCID: PMC4774364          DOI: 10.3892/etm.2016.2996

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  47 in total

1.  A clinico-microbiological study of diabetic foot ulcers in an Indian tertiary care hospital.

Authors:  Ravisekhar Gadepalli; Benu Dhawan; Vishnubhatla Sreenivas; Arti Kapil; A C Ammini; Rama Chaudhry
Journal:  Diabetes Care       Date:  2006-08       Impact factor: 19.112

2.  New insights in diabetic foot infection.

Authors:  Jean-Louis Richard; Albert Sotto; Jean-Philippe Lavigne
Journal:  World J Diabetes       Date:  2011-02-15

Review 3.  Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat.

Authors:  Hajo Grundmann; Marta Aires-de-Sousa; John Boyce; Edine Tiemersma
Journal:  Lancet       Date:  2006-09-02       Impact factor: 79.321

4.  Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem.

Authors:  C N Dang; Y D M Prasad; A J M Boulton; E B Jude
Journal:  Diabet Med       Date:  2003-02       Impact factor: 4.359

Review 5.  The continuing challenge of ESBLs.

Authors:  Federico Perez; Andrea Endimiani; Kristine M Hujer; Robert A Bonomo
Journal:  Curr Opin Pharmacol       Date:  2007-09-17       Impact factor: 5.547

6.  Costs of lower-extremity ulcers among patients with diabetes.

Authors:  Karen Stockl; Ann Vanderplas; Eskinder Tafesse; Eunice Chang
Journal:  Diabetes Care       Date:  2004-09       Impact factor: 19.112

7.  Antimicrobial susceptibility pattern of Staphylococcus aureus on clinical isolates and efficacy of laboratory tests to diagnose MRSA: a multi-centre study.

Authors:  Syed Zahid Bukhari; Safia Ahmed; Naheed Zia
Journal:  J Ayub Med Coll Abbottabad       Date:  2011 Jan-Mar

8.  Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship.

Authors:  Rebecca R Roberts; Bala Hota; Ibrar Ahmad; R Douglas Scott; Susan D Foster; Fauzia Abbasi; Shari Schabowski; Linda M Kampe; Ginevra G Ciavarella; Mark Supino; Jeremy Naples; Ralph Cordell; Stuart B Levy; Robert A Weinstein
Journal:  Clin Infect Dis       Date:  2009-10-15       Impact factor: 9.079

9.  Extended-spectrum β-lactamase producing Klebsiella pneumoniae from blood cultures in Puducherry, India.

Authors:  R M Parveen; M A Khan; G A Menezes; B N Harish; S C Parija; J P Hays
Journal:  Indian J Med Res       Date:  2011-09       Impact factor: 2.375

10.  The neuropathic diabetic foot ulcer microbiome is associated with clinical factors.

Authors:  Sue E Gardner; Stephen L Hillis; Kris Heilmann; Julia A Segre; Elizabeth A Grice
Journal:  Diabetes       Date:  2012-11-08       Impact factor: 9.461

View more
  4 in total

1.  First Report of bla CTX-M-15-Type ESBL-Producing Klebsiella pneumoniae in Wild Migratory Birds in Pakistan.

Authors:  Shahbaz Raza; Mashkoor Mohsin; Waqas Ahmed Madni; Fatima Sarwar; Muhammad Saqib; Bilal Aslam
Journal:  Ecohealth       Date:  2017-01-11       Impact factor: 3.184

2.  Bacterial ecology and antibiotic resistance mechanisms of isolated resistant strains from diabetic foot infections in the north west of Algeria.

Authors:  Bakhta Bouharkat; Aicha Tir Touil; Catherine Mullié; Nadia Chelli; Boumediene Meddah
Journal:  J Diabetes Metab Disord       Date:  2020-09-30

3.  Synergy and Order Effects of Antibiotics and Phages in Killing Pseudomonas aeruginosa Biofilms.

Authors:  Waqas Nasir Chaudhry; Jeniffer Concepción-Acevedo; Taehyun Park; Saadia Andleeb; James J Bull; Bruce R Levin
Journal:  PLoS One       Date:  2017-01-11       Impact factor: 3.240

4.  Multicentre study of the burden of multidrug-resistant bacteria in the aetiology of infected diabetic foot ulcers.

Authors:  Adeyemi T Adeyemo; Babatope Kolawole; Vincent O Rotimi; Aaron O Aboderin
Journal:  Afr J Lab Med       Date:  2021-03-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.